당뇨병 치료 기기 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Diabetes Care Devices Market reached USD 45.1 billion in 2023 and is projected to grow at a CAGR of 11.4% from 2024 to 2032. This market includes a wide range of devices designed to support individuals in managing their blood sugar levels and insulin therapy effectively, such as blood glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, syringes, and lancets.

The market is categorized into insulin delivery devices, blood glucose monitoring devices, syringes, and other tools. Blood glucose monitoring devices, which include self-monitoring blood glucose meters, continuous glucose monitors, testing strips, and lancets, represent the largest segment. These devices accounted for a significant share in 2023 and are expected to grow at 11.6% CAGR. These devices are essential for people with diabetes, allowing them to track their blood sugar levels and make informed decisions regarding diet, exercise, and insulin doses. Continuous monitoring helps prevent hypoglycemia and hyperglycemia, giving users greater control over their glucose levels and enhancing their ability to manage diabetes effectively.

The market is also segmented by end-user categories, which include hospitals, ambulatory surgical centers, diagnostic centers, homecare settings, and others. Hospitals are the largest end-user segment, accounting for a notable market share. These healthcare institutions are integral to diabetes care, offering comprehensive services that include diagnosis, treatment, and continuous monitoring. Hospitals require a diverse array of diabetes care devices, including glucose meters, insulin pumps, CGMs, and insulin pens, which are embedded into patient care protocols to support effective diabetes management.

The North American diabetes care devices market is led by the U.S., which generated the highest revenue in 2023. The country's healthcare system is one of the most advanced globally, with significant investments in cutting-edge diabetes care technologies. The robust healthcare expenditure in the U.S. plays a key role in driving the adoption of these devices, as it enables access to state-of-the-art treatment options. Additionally, a favorable regulatory environment supports the development and approval of new diabetes care technologies, fostering innovation and growth within the market.

Overall, the diabetes care devices market is poised for significant growth, driven by the rising prevalence of diabetes, increasing awareness of effective management solutions, and the continued advancement of medical technology.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of diabetes across the world
    • 3.2.1.2 Rising technological advancements in diabetes care devices
    • 3.2.1.3 Increasing investments by public and private organizations for diabetes care
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of diabetes care devices
    • 3.2.2.2 Rigorous regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Reimbursement scenario
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Blood glucose monitoring devices
  • 5.2.1 Self-monitoring blood glucose meters
  • 5.2.2 Continuous glucose monitors
  • 5.2.3 Testing strips
  • 5.2.4 Lancets
• 5.3 Insulin delivery devices
  • 5.3.1 Insulin pumps
    • 5.3.1.1 Tubed pumps
    • 5.3.1.2 Tubeless pumps
  • 5.3.2 Pens
    • 5.3.2.1 Reusable
    • 5.3.2.2 Disposable
  • 5.3.3 Pen needles
    • 5.3.3.1 Standard
    • 5.3.3.2 Safety
  • 5.3.4 Syringes
  • 5.3.5 Other insulin delivery devices

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospital
• 6.3 Ambulatory surgical centres
• 6.4 Diagnostic centres
• 6.5 Homecare
• 6.6 Other end users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 France
  • 7.3.3 UK
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Netherlands
  • 7.3.7 Sweden
  • 7.3.8 Belgium
  • 7.3.9 Denmark
  • 7.3.10 Finland
  • 7.3.11 Norway
  • 7.3.12 Lithuania
  • 7.3.13 Latvia
  • 7.3.14 Estonia
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Colombia
  • 7.5.5 Chile
  • 7.5.6 Peru
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Turkey
  • 7.6.5 Egypt
  • 7.6.6 Israel
  • 7.6.7 Kuwait
  • 7.6.8 Qatar

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 ARKRAY
• 8.3 Ascensia Diabetes Care Holding
• 8.4 B. Braun Melsungen
• 8.5 Becton, Dickinson and Company
• 8.6 Bionime Corporation
• 8.7 DarioHealth Corp.
• 8.8 Dexcom
• 8.9 Dr. Reddy's Laboratories
• 8.10 Eli Lilly and Company
• 8.11 F. Hoffmann-La Roche
• 8.12 Insulet Corporation
• 8.13 Medtronic
• 8.14 Nova Biomedical
• 8.15 Novo Nordisk
• 8.16 Pendiq
• 8.17 Platinum Equity Advisors
• 8.18 Sanofi
• 8.19 Sinocare
• 8.20 Tandem Diabetes Care
• 8.21 Ypsomed Holding